250 related articles for article (PubMed ID: 7524238)
1. Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer.
Grob BM; Schellhammer PF; Brassil DN; Wright GL
Urology; 1994 Oct; 44(4):525-9. PubMed ID: 7524238
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies.
Hakalahti L; Vihko P; Henttu P; Autio-Harmainen H; Soini Y; Vihko R
Int J Cancer; 1993 Oct; 55(4):590-7. PubMed ID: 7691762
[TBL] [Abstract][Full Text] [Related]
4. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Young CY; Klee GG; Tindall DJ; Bostwick DG
Urology; 1997 Jun; 49(6):857-62. PubMed ID: 9187691
[TBL] [Abstract][Full Text] [Related]
5. [Discrepancy between the serum levels of gamma seminoprotein and prostate-specific antigen in patients with prostatic neoplasms. Both true or either untrue].
Fujino A; Mukai N; Kawakami T; Yokoyama E; Mashimo S; Endo T; Ishibashi A; Koshiba K; Aoki Y; Itoh H
Nihon Hinyokika Gakkai Zasshi; 1991 Apr; 82(4):541-50. PubMed ID: 1711133
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
7. Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.
Turhan OI; Aydin NE; Sariyüce O; Ozkan S
Int Urol Nephrol; 1998; 30(6):731-44. PubMed ID: 10195869
[TBL] [Abstract][Full Text] [Related]
8. Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens.
Gallee MP; Visser-de Jong E; van der Korput JA; van der Kwast TH; ten Kate FJ; Schroeder FH; Trapman J
Urol Res; 1990; 18(3):181-7. PubMed ID: 1697709
[TBL] [Abstract][Full Text] [Related]
9. Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8.
Ljung G; Norberg M; Holmberg L; Busch C; Nilsson S
Prostate; 1997 May; 31(2):91-7. PubMed ID: 9140121
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen in the follow-up of prostatic adenocarcinoma treated with external beam radiation.
Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
Urol Int; 1991; 46(1):6-8. PubMed ID: 1708923
[TBL] [Abstract][Full Text] [Related]
11. Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP).
Garde SV; Sheth AR; Venkatesan VM; Panchal CJ; Porter AT; Grignon DJ
Cancer Lett; 1994 Apr; 78(1-3):11-7. PubMed ID: 7514089
[TBL] [Abstract][Full Text] [Related]
12. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
Ersev A; Ersev D; Turkeri L; Ilker Y; Simsek F; Kullu S; Akdas A
Prog Clin Biol Res; 1990; 357():129-34. PubMed ID: 1699237
[TBL] [Abstract][Full Text] [Related]
13. DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Berner A; Waere H; Nesland JM; Paus E; Danielsen HE; Fosså SD
Br J Urol; 1995 Jan; 75(1):26-32. PubMed ID: 7531589
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands.
Abrahamsson PA; Lilja H; Falkmer S; Wadström LB
Prostate; 1988; 12(1):39-46. PubMed ID: 2450341
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.
Chan TY; Mikolajczyk SD; Lecksell K; Shue MJ; Rittenhouse HG; Partin AW; Epstein JI
Urology; 2003 Jul; 62(1):177-81. PubMed ID: 12837462
[TBL] [Abstract][Full Text] [Related]
16. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line.
Henttu P; Vihko P
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):349-60. PubMed ID: 1373297
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.
Svanholm H; Hørder M
Scand J Urol Nephrol Suppl; 1988; 107():65-70. PubMed ID: 2453920
[TBL] [Abstract][Full Text] [Related]
18. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen as a marker of adenocarcinoma of prostate.
Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
Urol Res; 1989; 17(4):245-9. PubMed ID: 2475959
[TBL] [Abstract][Full Text] [Related]
20. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
